Palisade Bio, Inc. PALI NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

34/100

1/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Palisade Bio, Inc. (PALI) has a negative trailing P/E of -6.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -15.50%.

Criteria proven by this page:

VALUE (10/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -6.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -15.50%); analyst consensus target implies downside from the current price ($1.50, 27.2%).
Trailing Earnings Yield -15.50% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $1.50 (-27.2% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 33/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

34/100

SG Score

View full scorecard →

✗

VALUE

10/100

Price-to-Earnings & upside

Proven by this page

✓

FUTURE

64/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — PALI

Valuation Multiples

P/E (TTM)-6.5

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.84

P/S Ratio0.00

EV/EBITDA-10.5

Per Share Data

EPS (TTM)$-0.30

Book Value / Share$2.32

Revenue / Share$0.00

FCF / Share$-0.19

Yields & Fair Value

Earnings Yield-15.50%

Dividend Yield0.00%

Analyst Target$1.50 (-27.2%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-126.7	3.51	235.65	164,354.03	-
2017	-2,162.3	50.02	3,978.16	130,286.73	-
2018	-1,563.3	20.89	1,272.72	29,612.99	-
2019	-65.3	3.63	106.39	35,425.23	-
2020	-319.3	-0.28	-464.27	0.00	-
2021	-0.5	0.00	1.64	0.00	-
2022	-4.8	0.05	5.50	0.00	-
2023	-0.3	-0.01	0.36	16.14	-
2024	-0.2	0.00	0.31	0.00	-
2025	-7.8	0.08	1.01	0.00	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-126.11	$16.25K	$-21.08M	-129724.2%
2017	$-71.34	$260K	$-15.67M	-6025.4%
2018	$-18.02	$260K	$-4.93M	-1894.2%
2019	$-35.18	$15.39K	$-8.35M	-54254.9%
2020	$-186.00	$13.52K	$-10.32M	-76346.2%
2021	$-145.87	$0.00	$-26.62M	-
2022	$-16.53	$0.00	$-14.26M	-
2023	$-27.01	$250K	$-12.3M	-4920%
2024	$-1.69	$0.00	$-14.44M	-
2025	$-0.30	$0.00	$-16.78M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.25	$-0.39 – $-0.08	$27.87M	$27.87M – $27.87M	4
2027	$-0.30	$-0.41 – $-0.16	$47.71M	$47.71M – $47.71M	6
2028	$-0.50	$-0.94 – $-0.25	$121.55M	$121.55M – $121.55M	5
2029	$-0.45	$-0.45 – $-0.45	$415.33M	$415.33M – $415.33M	1
2030	$-0.38	$-0.38 – $-0.38	$1.08B	$1.08B – $1.08B	1